Announcing a significant step forward in the manufacture of our anti-viral GC Ink™, Haydale supplies plasma reactor to Rhode Island’s 401 Tech Bridge, for use in partnership with GC.
The HT200 Plasma Reactor will be utilised in the 401 Tech Bridge Advanced Materials and Technology Center, managed by the University of Rhode Island (URI), to support material commercialisation efforts of Graphene Composites and other local composites and textiles-based businesses. This adds to 401 Tech Bridge’s capability supporting its ambition to accelerate the adoption of new materials and support companies’ efforts in developing products that will change the world.
The HT200 incorporates Haydale’s patented functionalisation technologies which will be utilised by Graphene Composites, a nano-materials engineering company, for its newly developed anti-viral GC Ink™ and other products. GC Ink™ has been independently tested by Brown University in Rhode Island to show effectiveness at neutralising coronavirus and influenza viruses in under one minute, and the findings have been published on bioRxiv.
Christian Cowan, Tech Bridge 401 Executive Director, said: “Installing the Haydale equipment in the 401 Tech Bridge Advanced Materials & Technology Center will make it available to companies that are doing advanced materials research, enabling innovation and economic growth. We’re pleased to partner with Haydale, and to be working with Graphene Composites as they bring the GC Ink™ to market.”
Sandy Chen, Graphene Composites CEO & Co-Founder, said: “Having the ability to access the Haydale technology and unique innovation facilities at 401 Tech Bridge is a significant advancement to full commercialisation of our GC Ink™ as a powerful weapon against this pandemic and supporting the safe reopening of schools and public spaces.”
Keith Broadbent, Haydale CEO, added: “We are pleased to be working with 401 Tech Bridge and look forward to our technology helping the adoption of nanotechnology in composites in Rhode Island. Specifically, the increased global focus on a need for viral efficacy, it is great to see Haydale’s patented functionalisation process play such a key role in a solution.”